New combo tackles tough colorectal cancer in small trial
NCT ID NCT03828799
First seen Feb 28, 2026 · Last updated May 15, 2026 · Updated 13 times
Summary
This study tested a combination of two treatments (regorafenib and FOLFIRINOX) in 13 people with advanced colorectal cancer that has a specific gene change (RAS mutation). The main goal was to check safety and find the right dose. The study also looked at how long the cancer stayed under control. This is not a cure, but aims to manage the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Antoine Lacassagne
Nice, Alpes-Maritimes, 06189, France
-
Centre Cario - HPCA
Plérin, Finistère, 22190, France
-
Centre Georges-François Leclerc
Dijon, Côte d'Or, 21079, France
-
Institut du Cancer de Montpellier - Val d'Aurelle
Montpellier, 34298, France
Conditions
Explore the condition pages connected to this study.